Vaxcyte (PCVX) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $9.4B
- As of Nov 17, 2026
- P/E
- -8.18x
- Trailing twelve months
- P/B
- 3.77x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -46.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $9.4B
- As of Nov 17, 2026
- P/E
- -8.18x
- Trailing twelve months
- P/B
- 3.77x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -46.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-8.18x
Net loss — not comparable
P/B
3.77x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
-$7.27
Earnings per share
BPS
$15.75
Book value per share
ROE
-46.1%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $7.27 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $15.75 of net assets.
- ROE — shareholder equity shrank by 46.1% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Operating income decreased from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Operating income · same quarter, three years
Year-ago quarter -$242MDown
-$140M
Jul–Sep '24
-$242M
Jul–Sep '25
-$308M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Dhaliwal Harpreet S.Chief Technical Ops Officer · Nov 11, 2026Open-market sale17,000 shares · $1.2MAvg. price $67.8296
Show 3 price lots
- 9,345 shares × $68.156$637K
- 7,135 shares × $67.33$480K
- 520 shares × $68.819$36K
- Dhaliwal Harpreet S.Chief Technical Ops Officer · Nov 11, 2026Option exercise17,000 shares · $421KAvg. price $24.7985,085 shares held after
- Cowan ElviaSVP, Finance & CAO · Nov 2, 2026Open-market sale3,000 shares · $183KAvg. price $60.9178
Show 2 price lots
- 2,414 shares × $60.765$147K
- 586 shares × $61.547$36K
- Wassil JimEVP, Chief Scientific Ofc, COO · Nov 2, 2026Open-market sale2,250 shares · $137KAvg. price $60.8996
Show 2 price lots
- 1,907 shares × $60.779$116K
- 343 shares × $61.57$21K
- Cowan ElviaSVP, Finance & CAO · Nov 2, 2026Option exercise3,000 shares · $78KAvg. price $25.9230,860 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Nov 2, 2026Option exercise2,250 shares · $12KAvg. price $5.35147,685 shares held after
- Cowan ElviaSVP, Finance & CAO · Oct 5, 2026Open-market sale19,000 shares · $1.6MAvg. price $86.7427,860 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Oct 5, 2026Open-market sale18,000 shares · $1.6MAvg. price $86.74145,435 shares held after
- Cowan ElviaSVP, Finance & CAO · Oct 5, 2026Option exercise19,000 shares · $492KAvg. price $25.9246,860 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Oct 5, 2026Option exercise18,000 shares · $96KAvg. price $5.35163,435 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Oct 1, 2026Open-market sale2,250 shares · $128KAvg. price $56.6726
Show 2 price lots
- 2,155 shares × $56.654$122K
- 95 shares × $57.094$5K
- Wassil JimEVP, Chief Scientific Ofc, COO · Oct 1, 2026Option exercise2,250 shares · $12KAvg. price $5.35147,685 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Sep 9, 2026Open-market sale1,334 shares · $79KAvg. price $59.521145,435 shares held after
- PICKERING GRANTCHIEF EXECUTIVE OFFICER · Sep 8, 2026Shares withheld for taxes17,056 shares · $1.0MAvg. price $60.36429,902 shares held after
- Dhaliwal Harpreet S.Chief Technical Ops Officer · Sep 8, 2026Shares withheld for taxes7,651 shares · $462KAvg. price $60.3668,085 shares held after
- GUGGENHIME ANDREWPRESIDENT AND CFO · Sep 8, 2026Shares withheld for taxes7,155 shares · $432KAvg. price $60.3695,316 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Sep 8, 2026Shares withheld for taxes5,459 shares · $330KAvg. price $60.36146,769 shares held after
- Cowan ElviaSVP, Finance & CAO · Sep 8, 2026Shares withheld for taxes1,327 shares · $80KAvg. price $60.3627,860 shares held after
- Wassil JimEVP, Chief Scientific Ofc, COO · Sep 4, 2026Open-market sale1,381 shares · $84KAvg. price $61.16152,228 shares held after
- Jodar LuisChief Medical Officer · Sep 4, 2026Grant or award52,632 shares · $0Avg. price $052,632 shares held after
- PICKERING GRANTCHIEF EXECUTIVE OFFICER · Sep 2, 2026Shares withheld for taxes3,427 shares · $211KAvg. price $61.58446,958 shares held after
- GUGGENHIME ANDREWPRESIDENT AND CFO · Sep 2, 2026Shares withheld for taxes1,432 shares · $88KAvg. price $61.58102,471 shares held after
- Wassil JimCHIEF OPERATING OFFICER · Sep 2, 2026Shares withheld for taxes1,432 shares · $88KAvg. price $61.58153,609 shares held after
- Dhaliwal Harpreet S.Chief Technical Ops Officer · Sep 2, 2026Shares withheld for taxes659 shares · $41KAvg. price $61.5875,736 shares held after
- Cowan ElviaSVP, Finance & CAO · Sep 2, 2026Shares withheld for taxes326 shares · $20KAvg. price $61.5829,187 shares held after
- Wassil JimCHIEF OPERATING OFFICER · Sep 1, 2026Open-market sale3,477 shares · $212KAvg. price $61.0732
Show 4 price lots
- 1,537 shares × $60.886$94K
- 924 shares × $60.955$56K
- 713 shares × $61.481$44K
- 303 shares × $61.424$19K
- Wassil JimCHIEF OPERATING OFFICER · Sep 1, 2026Option exercise2,250 shares · $12KAvg. price $5.35158,518 shares held after
- PICKERING GRANTCHIEF EXECUTIVE OFFICER · Aug 31, 2026Shares withheld for taxes2,862 shares · $174KAvg. price $60.74450,385 shares held after
- Wassil JimCHIEF OPERATING OFFICER · Aug 31, 2026Shares withheld for taxes1,273 shares · $77KAvg. price $60.74156,268 shares held after
- GUGGENHIME ANDREWPRESIDENT AND CFO · Aug 31, 2026Shares withheld for taxes1,273 shares · $77KAvg. price $60.74103,903 shares held after
- Dhaliwal Harpreet S.Chief Technical Ops Officer · Aug 31, 2026Shares withheld for taxes361 shares · $22KAvg. price $60.7476,395 shares held after
- Cowan ElviaSVP, Finance & CAO · Aug 31, 2026Shares withheld for taxes243 shares · $15KAvg. price $60.7429,513 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Vaxcyte (PCVX) stock information
NASDAQ
Vaxcyte (PCVX) is listed on NASDAQ. Its market capitalization is about $9.4B. On trailing-twelve-month earnings the P/E ratio is -8.18, and the P/B ratio is 3.77. Return on equity is -46.1%. These figures are computed in-house from official filings and are reference information only.
Vaxcyte — frequently asked questions
- What is the P/E ratio of Vaxcyte (PCVX)?
- On a trailing-twelve-month basis, PCVX trades at a P/E ratio of -8.18. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Vaxcyte?
- PCVX has a market capitalization of about $9.4B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.